In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination
by
Shigetaka Shimodaira 1,2,*, Ryu Yanagisawa 2, Terutsugu Koya 1, Koichi Hirabayashi 2, Yumiko Higuchi 3, Takuya Sakamoto 1
, Misa Togi 1, Tomohisa Kato, Jr. 1, Takashi Kobayashi 4, Tomonobu Koizumi 4, Shigeo Koido 5 and Haruo Sugiyama 6
Shigetaka Shimodaira 1,2,*, Ryu Yanagisawa 2, Terutsugu Koya 1, Koichi Hirabayashi 2, Yumiko Higuchi 3, Takuya Sakamoto 1, Misa Togi 1, Tomohisa Kato, Jr. 1, Takashi Kobayashi 4, Tomonobu Koizumi 4, Shigeo Koido 5 and Haruo Sugiyama 6
1
Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan
2
Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 390-8621, Japan
3
Department of Clinical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
4
Shinshu Cancer Center, Shinshu University Hospital, Matsumoto 390-8621, Japan
5
Department of Gastroenterology and Hepatology, The Jikei University School of Medicine, Kashiwa, Chiba 277-8567, Japan
6
Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
*
Author to whom correspondence should be addressed.
Vaccines 2019, 7(3), 120; https://doi.org/10.3390/vaccines7030120
Received: 3 August 2019 / Revised: 12 September 2019 / Accepted: 17 September 2019 / Published: 19 September 2019
(This article belongs to the Section Cancer Vaccines and Immunotheraphy)
Significant recent advances in cancer immunotherapeutics include the vaccination of cancer patients with tumor antigen-associated peptide-pulsed dendritic cells (DCs). DC vaccines with homogeneous, mature, and functional activities are required to achieve effective acquired immunity; however, the yield of autologous monocyte-derived DCs varies in each patient. Priming with a low dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF) 16–18 h prior to apheresis resulted in 50% more harvested monocytes, with a significant increase in the ratio of CD11c+CD80+ DCs/apheresed monocytes. The detection of antigen-specific cytotoxic T lymphocytes after Wilms’ tumor 1-pulsed DC vaccination was higher in patients treated with rhG-CSF than those who were not, based on immune monitoring using tetramer analysis. Our study is the first to report that DC vaccines for cancer immunotherapy primed with low-dose rhG-CSF are expected to achieve higher acquired immunogenicity.
View Full-Text
Keywords:
dendritic cell; cancer vaccine; vaccination; acquired immunity; granulocyte colony-stimulating factor; tetramer analysis
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Shimodaira, S.; Yanagisawa, R.; Koya, T.; Hirabayashi, K.; Higuchi, Y.; Sakamoto, T.; Togi, M.; Kato, T., Jr.; Kobayashi, T.; Koizumi, T.; Koido, S.; Sugiyama, H. In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. Vaccines 2019, 7, 120.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
